The Chinese company Grand Pharmaceutical Group Ltd (0512.HK) has committed to invest €15 million in equity and license fees, as a cornerstone funding for Xeltis ongoing Series D2 financing round. The Grand Pharma commitment [...]

For first-hand experience with Xeltis restorative hemodialysis vascular access device aXess, there is a very insightful article by Doctor Jan De Letter in the latest issue of AZ Link magazine. Dr De Letter is [...]

Xeltis hired Dr Paulo Neves as Vice President for Clinical and Medical Affairs. Paulo brings to Xeltis remarkable medical experience as a practicing cardiac surgeon and pioneering implanter of a number of cardiovascular medical [...]

Results from novel imaging analysis of the Endogenous Tissue Restoration (ETR) process in Xeltis’ devices further advance the understanding of in vivo polymer absorption and neotissue formation. The outcomes have been obtained using a [...]

CEO Eliane Schutte shared how Xeltis restorative devices can help combine clinical needs with a patient-centric approach in cardiovascular treatment. Speaking today at LSX World Congress 2022 in London, Eliane explained how the most advanced [...]

Preliminary results from a clinical trial of Xeltis’ restorative hemodialysis access graft, aXess, showed very promising early puncturing, functional patency and safety data. The data, from the ongoing first-in-human aXess trial, will be presented [...]

Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess is prominently discussed among promising novel devices in vascular access. According to RI, aXess [...]

Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients. An article published in peer-reviewed journal Materials Today showcases how Xeltis implanted the first clinical devices made of supramolecular biomaterials [...]